Breast cancer heterogeneity: Need to review current treatment strategies

Fayaz Malik, Hasan Korkaya, Shawn G. Clouthier, Max S. Wicha

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although the heterogeneity of breast cancer has long been recognized, the hierarchical organization and existence of tumor initiating subpopulation within breast tumors was not known until the last decade. These tumor initiating cells called cancer stem cells (CSCs) display features of stem cells such as unlimited ability to self-renew and lineage differentiation. Accumulating evidence now suggests that by virtue of their relative resistance to both radiation and chemotherapy, these cells contribute to resistance and relapse following therapy. Utilizing cell cultures and mouse xenograft models, we and others demonstrated that breast CSCs have far greater invasive and metastatic potential than differentiated tumor cells which comprise the tumor bulk. Altogether, these studies suggest that targeting and elimination of breast CSCs may be required to improve patient outcome. In this review, we will discuss recent developments in breast CSC research and advances in CSC specific targeted therapies that are in preclinical and clinical trials.

Original languageEnglish (US)
Pages (from-to)225-231
Number of pages7
JournalCurrent Breast Cancer Reports
Volume4
Issue number4
DOIs
StatePublished - Dec 1 2012

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Therapeutics
Stem Cell Research
Neoplasms
Heterografts
Stem Cells
Cell Culture Techniques
Clinical Trials
Radiation
Recurrence
Drug Therapy

Keywords

  • Breast cancer
  • Breast cancer subtypes
  • Cancer stem cells
  • Circulating tumor cells
  • Drug resistance
  • HER2
  • Luminal
  • Metastasis
  • Trastazumab
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Oncology

Cite this

Breast cancer heterogeneity : Need to review current treatment strategies. / Malik, Fayaz; Korkaya, Hasan; Clouthier, Shawn G.; Wicha, Max S.

In: Current Breast Cancer Reports, Vol. 4, No. 4, 01.12.2012, p. 225-231.

Research output: Contribution to journalArticle

Malik, Fayaz ; Korkaya, Hasan ; Clouthier, Shawn G. ; Wicha, Max S. / Breast cancer heterogeneity : Need to review current treatment strategies. In: Current Breast Cancer Reports. 2012 ; Vol. 4, No. 4. pp. 225-231.
@article{d8c7d7456ba84382aebcee8c976541b6,
title = "Breast cancer heterogeneity: Need to review current treatment strategies",
abstract = "Although the heterogeneity of breast cancer has long been recognized, the hierarchical organization and existence of tumor initiating subpopulation within breast tumors was not known until the last decade. These tumor initiating cells called cancer stem cells (CSCs) display features of stem cells such as unlimited ability to self-renew and lineage differentiation. Accumulating evidence now suggests that by virtue of their relative resistance to both radiation and chemotherapy, these cells contribute to resistance and relapse following therapy. Utilizing cell cultures and mouse xenograft models, we and others demonstrated that breast CSCs have far greater invasive and metastatic potential than differentiated tumor cells which comprise the tumor bulk. Altogether, these studies suggest that targeting and elimination of breast CSCs may be required to improve patient outcome. In this review, we will discuss recent developments in breast CSC research and advances in CSC specific targeted therapies that are in preclinical and clinical trials.",
keywords = "Breast cancer, Breast cancer subtypes, Cancer stem cells, Circulating tumor cells, Drug resistance, HER2, Luminal, Metastasis, Trastazumab, Tumor heterogeneity",
author = "Fayaz Malik and Hasan Korkaya and Clouthier, {Shawn G.} and Wicha, {Max S.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1007/s12609-012-0093-5",
language = "English (US)",
volume = "4",
pages = "225--231",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Breast cancer heterogeneity

T2 - Need to review current treatment strategies

AU - Malik, Fayaz

AU - Korkaya, Hasan

AU - Clouthier, Shawn G.

AU - Wicha, Max S.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Although the heterogeneity of breast cancer has long been recognized, the hierarchical organization and existence of tumor initiating subpopulation within breast tumors was not known until the last decade. These tumor initiating cells called cancer stem cells (CSCs) display features of stem cells such as unlimited ability to self-renew and lineage differentiation. Accumulating evidence now suggests that by virtue of their relative resistance to both radiation and chemotherapy, these cells contribute to resistance and relapse following therapy. Utilizing cell cultures and mouse xenograft models, we and others demonstrated that breast CSCs have far greater invasive and metastatic potential than differentiated tumor cells which comprise the tumor bulk. Altogether, these studies suggest that targeting and elimination of breast CSCs may be required to improve patient outcome. In this review, we will discuss recent developments in breast CSC research and advances in CSC specific targeted therapies that are in preclinical and clinical trials.

AB - Although the heterogeneity of breast cancer has long been recognized, the hierarchical organization and existence of tumor initiating subpopulation within breast tumors was not known until the last decade. These tumor initiating cells called cancer stem cells (CSCs) display features of stem cells such as unlimited ability to self-renew and lineage differentiation. Accumulating evidence now suggests that by virtue of their relative resistance to both radiation and chemotherapy, these cells contribute to resistance and relapse following therapy. Utilizing cell cultures and mouse xenograft models, we and others demonstrated that breast CSCs have far greater invasive and metastatic potential than differentiated tumor cells which comprise the tumor bulk. Altogether, these studies suggest that targeting and elimination of breast CSCs may be required to improve patient outcome. In this review, we will discuss recent developments in breast CSC research and advances in CSC specific targeted therapies that are in preclinical and clinical trials.

KW - Breast cancer

KW - Breast cancer subtypes

KW - Cancer stem cells

KW - Circulating tumor cells

KW - Drug resistance

KW - HER2

KW - Luminal

KW - Metastasis

KW - Trastazumab

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84872197199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872197199&partnerID=8YFLogxK

U2 - 10.1007/s12609-012-0093-5

DO - 10.1007/s12609-012-0093-5

M3 - Article

AN - SCOPUS:84872197199

VL - 4

SP - 225

EP - 231

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 4

ER -